Skip to main content

Sandoz decides on Basel for headquarters

| News

Sandoz decides on Basel for headquarters


Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected to take place in the second half of 2023. Sandoz plans to move from the Novartis campus to its new headquarters in the center in mid-2024.

Sandoz CEO Richard Saynor values Basel as "a global center for the life sciences industry" (image: Sandoz)

Sandoz AG, which specializes in generics and biosimilars, will set up its permanent headquarters in the center of Basel after separating from Novartis in future. According to a press release, Sandoz will move its headquarters from the Novartis campus to the Elsässertor office building in the center of Basel next to the train station after the separation in mid-2024.

CEO of Sandoz Richard Saynor stated in a press release that he is delighted that the company will continue to call Basel its home. He adds: “Our planned location in the heart of the city will allow us to create a working environment that meets our business needs and reflects our identity, culture, and values. Basel is a global center for the life sciences industry, attracting an unrivalled pool of talent and experience that will help us to grow further and achieve our ambition of being the sustainable global leader in generics and biosimilars.”

New working environment

The move will have no effect on the management of Sandoz’s global business according to the information provided. The new working environment will be designed to enable close collaboration and teamwork across the entire organization.

The pharmaceutical company Novartis announced its intention to separate from Sandoz in August 2022. At Novartis, Sandoz was led as a division for patent-free drugs. The planned separation is expected to take place in the second half of 2023. As an independent company, Sandoz will then list on the SIX Swiss Exchange.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Forty51 Ventures invests to found Mysthera Therapeutics

Mysthera Therapeutics AG has been founded in Basel. Forty51 Ventures, a venture capital firm also based in Basel, has provided...
Read More

Spexis receives capital commitment of 2.5 million US dollars

Investors have made an additional capital commitment to Spexis AG, based in the Basel Area. With an extra 2.5 million...
Read More

Do you have a question? We'd like to hear from you.